The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments

Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely expl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in immunology Jg. 8; S. 631
Hauptverfasser: Veluchamy, John P., Kok, Nina, van der Vliet, Hans J., Verheul, Henk M. W., de Gruijl, Tanja D., Spanholtz, Jan
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland Frontiers Media S.A 31.05.2017
Schlagworte:
adoptive natural killer cell therapy
allogeneic natural killer cells
autologous natural killer cells
hematopoietic stem cell transplantation
Immunology
natural killer cell biotech companies
natural killer cell combinatorial studies
adoptive natural killer cell therapy
hematopoietic stem cell transplantation
natural killer cell combinatorial studies
allogeneic natural killer cells
natural killer cell biotech companies
autologous natural killer cells
ISSN:1664-3224, 1664-3224
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely explored in cancer immunotherapy. Early studies from autologous NK cells have failed to demonstrate significant clinical benefit. In this review, the clinical benefits of adoptively transferred allogeneic NK cells in a transplant and non-transplant setting are compared and discussed in the context of relevant NK cell platforms that are being developed and optimized by various biotech industries with a special focus on augmenting NK cell functions.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Specialty section: This article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in Immunology
Edited by: Gianfranco Pittari, Hamad Medical Corporation, Qatar
These authors have contributed equally to this work.
Reviewed by: Evelyn Ullrich, Goethe University Frankfurt, Germany; Bjarne Kuno Møller, Aarhus University Hospital, Denmark
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2017.00631